T-Cell Antigen Drug Discovery Program

Novel Tumor Antigens

Along with the early success of checkpoint inhibitors, adoptive immunotherapy by transfer of genetically-altered T-cells has emerged to be of significant interest in the immune-oncology market.   Our clinical studies and marketed product manufacturing protocol will provide us with the unique ability to collect T-cells from patients, both pre- and post- vaccine administration. Our objective is to use T-cells made responsive to by BioVaxys’s vaccines to identify new antigens that can be synthesized and explored; they may prove useful as diagnostic agents or as new, chemically-defined, patient-specific vaccines. These novel antigens may be distinct for each patient or for groups of patients.